{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.56","value":"5.73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Described via means and standard deviations in available Arm C relapse samples","dispersionType":"Standard Deviation","groups":[{"description":"Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)","id":"OG000","title":"Arm C (Safety/Efficacy Dose Level 2)"}],"paramType":"MEAN","populationDescription":"Arm C Dose Level 2 patients who relapsed and had data collected.","reportingStatus":"POSTED","timeFrame":"At relapse (up to 3 years)","title":"Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts","type":"SECONDARY","unitOfMeasure":"qPCR fold expression ratio"}